Improving Lives Through Early Detection: Abu Dhabi’s New Colon Cancer Test

Did you know that colon cancer is the second leading cause of cancer-related deaths globally? According to the World Health Organization, over 1.9 million new colorectal cancer cases were recorded in 2020, resulting in more than 930,000 deaths. In Abu Dhabi alone, colon cancer accounts for 8% of cases. Data from 2023 revealed that 67% of such cases were diagnosed at late stages, significantly limiting treatment options and reducing survival rates. 

To address this, Abu Dhabi has launched an innovative blood test called liquid biopsy designed to enhance early detection and encourage broader participation in screenings.

The Science Behind the Test

The non-invasive liquid biopsy involves a simple blood draw and provides an easy alternative to traditional colonoscopies. Though it doesn’t replace the gold-standard colonoscopy, the test serves as a complementary tool. Patients testing positive will still need confirmation through a colonoscopy, while those testing negative can follow up with another test in three years. 

Currently, samples are processed in labs outside the UAE, leading to a turnaround time of approximately five weeks. However, ongoing efforts aim to localize this capability, reducing waiting times and further streamlining the process.

Tailored Screening for Those at Risk

The program specifically targets individuals aged 50 and above without a family history of colorectal cancer and those aged 40-plus with such a history. This initiative is critical, as many cases in Abu Dhabi are detected only after symptoms, such as abdominal pain or rectal bleeding, indicate advanced stages.

Routine screenings in Abu Dhabi remain underutilized, with participation rates below 20%. Factors such as fear, cultural stigmas, and misconceptions about risk, especially among men, have hindered adoption. By offering a more comfortable and less invasive option, the new blood test hopes to overcome these barriers and promote regular screening.

UAE’s Drive for Innovation in Healthcare

The introduction of this blood test is part of a broader strategy to position the UAE as a leader in healthcare innovation. With the involvement of cutting-edge local health technology companies and initiatives to reduce dependence on international labs, the UAE is at the forefront of integrating advanced diagnostics into routine care.

Moreover, while the focus is currently on colorectal cancer, the potential applications of liquid biopsy technology extend to other cancers, such as prostate and pancreatic. This highlights the UAE’s commitment to advancing personalized and preventive healthcare solutions.

Accessible Screening for All

The blood test is now available at select Ambulatory Health Services (AHS) clinics and Healthpoint Hospital across Abu Dhabi, Al Ain, and Al Dhafra. Targeted individuals include those over 50 who haven’t had a colonoscopy in the past 10 years or a FIT (fecal immunochemical test) in the past year. Those with a family history of colorectal cancer or lifestyle risk factors are also eligible. 

With this groundbreaking initiative, Abu Dhabi aims to significantly reduce late-stage diagnoses, improve survival rates, and set a benchmark for healthcare innovation in the region. The new test not only underscores the importance of early detection but also demonstrates the emirate’s commitment to leveraging cutting-edge technology to enhance public health outcomes.

Connect with Global Healthcare Leaders at MedTech World Dubai 2025

Join MedTech World Dubai 2025 to connect with startup founders, investors, government officials, and healthcare innovators. Participate in panel discussions, network with industry leaders, and attend the awards gala. Experience insightful sessions, pitch competition, and GCC hospitality. Register today for MedTech World Dubai 2025!